Circular RNA regulators of common drug-eliminating genes

常见药物消除基因的环状RNA调节因子

基本信息

  • 批准号:
    10684130
  • 负责人:
  • 金额:
    $ 24.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-15 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Children signify a population with highly dynamic physiology and pharmacology at increased vulnerability to drug toxicities. Biotransformation genes, commonly referred to as drug metabolizing enzymes and transporters, have both pharmacological and toxicological significance. We have shown a robust postnatal surge in hepatic expression of all biotransformation genes tested. In striking contrast, these very genes did not show such surge in the duodenum, another major biotransformation organ. Interestingly, CYP3A4 mRNA (cytochrome P450) decreased with age but CYP3A4 protein increased in the duodenum. Circular RNAs (circRNAs) are emerging regulators and implicated to increase protein production by functioning as microRNA sponges. As described in the Preliminary Study, we have shown the presence of circRNAs for CES1 (carboxylesterase-1), CES2, CYP3A4, and PXR (pregnane x receptor, a master regulator of biotransformation genes). Their expression patterns varied between the liver and duodenum as well as age. The central hypothesis of the proposed project is that circRNAs regulate the expression of biotransformation and related genes in an age and organ-dependent manner. The Specific Aims are: (1) to characterize sequences and functionality of circRNAs for biotransformation genes, and (2) to specify molecular actions of the circRNAs for regulatory activities. To specify the functionality of circRNAs, the authenticity of detected circRNAs will be sequence-confirmed, their organ/age-specific expression will be determined; and their regulatory activities toward their parent and related genes will be specified. To ascertain the molecular action for the regulatory activity, a circRNA will be tested for altered transcription rate, decay of mRNA, translational efficiency and protein stability of a target gene. The circRNA-miRNA-mRNA network, known to support the sponging mechanism, will be constructed bioinformatically for different organs. The scientific premise is strong and original. The originality stems from the novelty of circRNAs as critical regulators of biotransformation genes and the dependence of their regulatory activity on age and an organ. circRNAs have been increasingly recognized to exert critical pathophysiological functions, however, their presence and functionality for biotransformation genes remain largely unknown. These studies will have filled knowledge gaps on how circRNAs participate in regulating biotransformation genes, critical determinants in drug efficacy and safety. Clearly, information collected will serve a strong foundation for a bigger project.
儿童意味着具有高度动态生理学和药理学的人群, 药物毒性生物转化基因,通常被称为药物代谢酶, 转运蛋白,具有药理学和毒理学意义。我们已经显示出一个强大的产后 检测的所有生物转化基因的肝脏表达激增。与此形成鲜明对比的是, 在另一个主要的生物转化器官--十二指肠中显示出这种激增。有趣的是,CYP 3A 4 mRNA 细胞色素P450(CYP 3A 4)在十二指肠中随年龄的增长而下降,而蛋白质含量则随年龄的增长而增加。环状rna circRNA是一种新兴的调节因子,通过作为microRNA发挥作用, 海绵如在初步研究中所述,我们已经证明了CES 1的circRNA的存在。 (羧酸酯酶-1)、CES 2、CYP 3A 4和PXR(胆固醇X受体,生物转化的主要调节剂 基因)。它们的表达模式在肝脏和十二指肠以及年龄之间变化。中央 所提出的项目的假设是,circRNA调节生物转化和相关的表达, 以年龄和器官依赖的方式改变基因。具体目的是:(1)表征序列, (2)确定circRNA对生物转化基因的分子作用, 监管活动。为了指定circRNA的功能,将检测到的circRNA的真实性。 序列确认后,将确定其器官/年龄特异性表达; 将指定它们的亲本和相关基因。为了确定调节的分子作用, 活性,将测试circRNA的转录速率改变、mRNA衰减、翻译效率和 靶基因的蛋白质稳定性。circRNA-miRNA-mRNA网络,已知支持海绵状 机制,将构建不同器官的生物信息学。科学前提是强有力的, 原始.其独创性源于circRNA作为生物转化基因关键调节因子的新奇 以及它们的调节活性对年龄和器官的依赖性。circRNA已经越来越多地 被认为发挥关键的病理生理功能,然而,它们的存在和功能, 生物转化基因仍然是未知的。这些研究将填补知识空白, circRNA参与调节生物转化基因,这是药物功效和安全性的关键决定因素。 显然,收集的信息将为更大的项目奠定坚实的基础。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.
共价 CES2 抑制剂可防止抗癌药物伊立替康减少肠道类器官的形成。
  • DOI:
    10.2174/1389200224666221212143904
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    2.3
  • 作者:
    Eades,William;Liu,William;Shen,Yue;Shi,Zhanquan;Yan,Bingfang
  • 通讯作者:
    Yan,Bingfang
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
  • DOI:
    10.1016/j.bcp.2022.115224
  • 发表时间:
    2022-10
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Liu, William;Yu, Sarah;Yan, Bingfang
  • 通讯作者:
    Yan, Bingfang
Differentiated embryonic chondrocyte expressed gene-1 is a central signaling component in the development of collagen-induced rheumatoid arthritis.
分化的胚胎软骨细胞表达的gene-1是胶原诱导的类风湿性关节炎发展中的核心信号成分。
  • DOI:
    10.1016/j.jbc.2023.102982
  • 发表时间:
    2023-03
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Wu, Yichen;Wang, Haobin;Huo, Ying;Yan, Bingfang;Honda, Hiroaki;Liu, Wei;Yang, Jian
  • 通讯作者:
    Yang, Jian
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bingfang Yan其他文献

Bingfang Yan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bingfang Yan', 18)}}的其他基金

Functional connection between the growth factor independence-1b and post-neonatal regulation of biotransformation genes
生长因子独立1b与生物转化基因新生儿后调控之间的功能联系
  • 批准号:
    10681617
  • 财政年份:
    2023
  • 资助金额:
    $ 24.3万
  • 项目类别:
Metabolism-based interactions and organ-targeted delivery of molnupiravir, nirmatrelvir and remdesivir
莫努匹拉韦、尼马曲韦和瑞德西韦基于代谢的相互作用和器官靶向递送
  • 批准号:
    10561381
  • 财政年份:
    2023
  • 资助金额:
    $ 24.3万
  • 项目类别:
Circular RNA regulators of common drug-eliminating genes
常见药物消除基因的环状RNA调节因子
  • 批准号:
    10507852
  • 财政年份:
    2022
  • 资助金额:
    $ 24.3万
  • 项目类别:
Metabolic basis for lipid abnormality with anti-HIV tenofovir prodrugs
抗HIV替诺福韦前药脂质异常的代谢基础
  • 批准号:
    10026409
  • 财政年份:
    2020
  • 资助金额:
    $ 24.3万
  • 项目类别:
Metabolic basis for lipid abnormality with anti-HIV tenofovir prodrugs
抗HIV替诺福韦前药脂质异常的代谢基础
  • 批准号:
    10254403
  • 财政年份:
    2020
  • 资助金额:
    $ 24.3万
  • 项目类别:
Biodegradable hollow CUS nanoparticles for photothermal cancer therapy
用于光热癌症治疗的可生物降解的中空 CUS 纳米颗粒
  • 批准号:
    9657958
  • 财政年份:
    2018
  • 资助金额:
    $ 24.3万
  • 项目类别:
Interplay between metabolism and FXR activation in scoparone signaling
scoparone 信号传导中代谢与 FXR 激活之间的相互作用
  • 批准号:
    8574018
  • 财政年份:
    2013
  • 资助金额:
    $ 24.3万
  • 项目类别:
Signaling of the Pregnane X Receptor
孕烷 X 受体的信号传导
  • 批准号:
    7831855
  • 财政年份:
    2009
  • 资助金额:
    $ 24.3万
  • 项目类别:
BRIN: URI: TMSR/FUNCTIONAL GENOMICS & PROTEOMICS SUBCORE
BRIN: URI: TMSR/功能基因组学
  • 批准号:
    6973512
  • 财政年份:
    2004
  • 资助金额:
    $ 24.3万
  • 项目类别:
SIGNALING OF PREGNANE X RECEPTOR
妊娠 X 受体的信号传导
  • 批准号:
    6387275
  • 财政年份:
    2000
  • 资助金额:
    $ 24.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了